Targeted Genetics clinical hold following patient death
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA places clinical hold on Targeted Genetics' gene therapy trial with tgAAC94 for the treatment of inflammatory arthritis following the death of a 36-year-old woman, the biotech announces July 24. The biologic uses a recombinant adeno-associated virus (AAV) derived vector to deliver a gene encoding the protein TNFR:fc, a soluble form of the tumor necrosis factor alpha receptor, to reduce inflammation and disease in patients with active inflammatory arthritis. Since the trial began in October 2005, 127 subjects have received an initial dose of active drug or placebo, and an additional 74 subjects received a second dose of active drug, according to Targeted Genetics...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.